Form 8-K - Current report:
SEC Accession No. 0001104659-11-000565
Filing Date
2011-01-06
Accepted
2011-01-06 08:06:31
Documents
5
Period of Report
2010-12-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a11-1130_18k.htm 8-K 51957
2 EX-5.1 a11-1130_1ex5d1.htm EX-5.1 12484
3 EX-10.1.1 a11-1130_1ex10d1d1.htm EX-10.1.1 481619
4 EX-10.1.2 a11-1130_1ex10d1d2.htm EX-10.1.2 18068
5 EX-10.1.3 a11-1130_1ex10d1d3.htm EX-10.1.3 304073
  Complete submission text file 0001104659-11-000565.txt   870229
Mailing Address 119 FOURTH AVE NEEDHAM MA 02494-2725
Business Address 119 FOURTH AVE NEEDHAM MA 02494 7814330771
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-15006 | Film No.: 11512797
SIC: 2835 In Vitro & In Vivo Diagnostic Substances